Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1b Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors

NCT02235688 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT02235688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02235688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1b Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2014
Completion date
January 31, 2017
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumors